Recurrent Pneumonitis Induced by Atezolizumab (Anti-Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis

J Thorac Oncol. 2018 Nov;13(11):e227-e230. doi: 10.1016/j.jtho.2018.06.022.

Authors

Ping-Chih Hsu¹, Shih-Hong Li¹, Cheng-Ta Yang²

Affiliations

¹ Department of Thoracic Medicine, Chung Gung Memorial Hospital, Linkou, Taiwan.
² College of Medicine, Chung Gung University and the Department of Thoracic Medicine, Chung Gung Memorial Hospital, Taoyuan, Taiwan. Electronic address: yang1946@cgmh.org.tw.

PMID: 30368415
DOI: 10.1016/j.jtho.2018.06.022

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / adverse effects*
Carcinoma, Non-Small-Cell Lung / complications*
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / pathology
Humans
Immunotherapy / methods*
Lung Neoplasms / complications*
Lung Neoplasms / drug therapy
Lung Neoplasms / pathology
Male
Middle Aged
Pneumonia / chemically induced*
Pneumonia / pathology

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
atezolizumab